20/20 Biolabs (NASDAQ:AIDX) Releases Earnings Results

20/20 Biolabs (NASDAQ:AIDX) released its quarterly earnings data on Friday. The company reported ($0.26) earnings per share for the quarter, FiscalAI reports. The firm had revenue of $0.73 million during the quarter.

20/20 Biolabs Trading Up 5.9%

Shares of NASDAQ:AIDX traded up $0.03 during mid-day trading on Friday, reaching $0.55. 228,359 shares of the stock were exchanged, compared to its average volume of 105,424. The business’s 50 day moving average price is $0.57. 20/20 Biolabs has a one year low of $0.40 and a one year high of $50.00. The company has a market capitalization of $6.73 million and a P/E ratio of -1.96.

Wall Street Analyst Weigh In

AIDX has been the topic of several research analyst reports. Weiss Ratings upgraded shares of 20/20 Biolabs from a “sell (e-)” rating to a “sell (e)” rating in a report on Monday, August 3rd. Maxim Group began coverage on shares of 20/20 Biolabs in a research report on Monday, May 11th. They set a “buy” rating and a $5.00 price objective for the company. One investment analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $5.00.

20/20 Biolabs Company Profile

We develop and commercialize AI-powered, laboratory-based blood tests for the early detection and prevention of cancers and chronic diseases. We offer two families of lab tests, both under our OneTest brand: (i) OneTest for Cancer, a multi-cancer early detection, or MCED, blood test which has been our primary commercial focus and source of revenues since we wound down our COVID-19 testing business, and (ii) OneTest for Longevity, which measures inflammatory biomarkers, that we expect to launch in the first half of 2026.